• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

The Market Outlook for the Week Ahead, or Recession Fears Arise

Diary, Newsletter

I hate to be the bearer of bad news, but the US is now looking at the ugly face of recession. Both oil shocks of the last 50 years promptly delivered serious recessions and the third one could well do the same.

Q1 is now Looking Like a Write Off, as analysts rush to pare forecasts. Some are cutting predictions from 5% growth to zero, or even negative numbers. There will be no sustainable stock market rally until this situation reverses in H2. Keep selling those rallies.

There is no denying that oil at $132 is starting to seriously drag on the economy. Here in San Francisco, gasoline has topped $7.00 a gallon. The good news is that high prices will pay for the enormous losses big oil will take writing off hundreds of billions of Russian investments. It will also greatly accelerate the move to electric vehicles. No wonder Tesla (TSLA) is holding up so well.

We may duck the bullet this time because the number of barrels needed to produce a unit of GDP has dropped by half since over the past half-century, thanks to conservation, improved technology, and the advent of electric vehicles. That old Lincoln Continental that guzzled 8 miles a gallon now gets 27.

The big issue will be how long it will take Germany to replace Russian gas. The US can do it easily, but it will take years to build out the infrastructure and build the ships. The big Russian strategic mistake is that they launched their war in the spring, just when German gas needs decline dramatically.

A second Cold War, a third oil shock, and a hot shooting war are a lot for markets to take in in only three weeks. It all means lower share prices….for now. It makes my down 20% target look pretty good.

There is one other matter that may save our bacon. The real economy is still hot, and the world is running out of everything. Oil was going to $130 anyway, even without the war.

Food, housing, materials, commodities, aluminum, steel, lumber, you name it. All are in short supply. And you already own the things these commodities make, like your home, you already have a hedge and a great long-term play.

This is not what recessions are made out of.

The US Bans Russian Oil Imports, and the rush is on to see how fast we can replace German imports. It’s also looking like several hundred billion dollars of Russian investment in illiquid long-term investments will be trapped in the US, such as in real estate, joint ventures, and venture capital. I keep pinching myself to see this WWII replay unfold. The Mad Hedge Market Timing Index just hit a one-year low at 13. Defense stocks are soaring.

Commodity Prices are soaring anywhere Russia is a major supplier. Nickel prices are up 90% and oil hit $133 a barrel. It all throws gasoline on the inflation fire.

Gold breaks $2,000, a new 18-month high, on a massive flight to safety bid. Next stop could be $3,000.

Nickel Prices soar 250%, to $100,000 a metric tonne, with Russia as a major producer. Futures trading is halted on the London Metals Exchange. Who is the biggest user of nickel? China at 59% and the rest of Asia for a further 23%, mostly to produce stainless steel. More supply disruptions to come. US automakers are scrambling, the biggest end-users of stainless steel. Car prices are about to rocket accelerating the move to carbon fiber.

Europe to Cut Russian Gas Purchases by Two Thirds This Year, some 45% of their current gas supply. They will essentially bring their renewable targets forward by a decade, which is moving forward much faster than the US. Oil is just too unreliable to depend on. Some are untried on a mass scale, such as using wind and solar power to electrolyze water to make clean hydrogen. It’s great if they can pull it off.

CPI Inflation Data comes in at a Red Hot 7.9% YOY, a new cycle high and a new 40-year high, and 0.8% for the month of February. Wars are highly inflationary, especially when they come on top of already chronic supply shorts and supply chain disruptions. Bonds are getting crushed. Too bad I’m triple short.

Weekly Jobless Claims
come in at 227,000, with Continuing Claims at 1,494,000. Hot jobs demand downplays the risk of the Ukraine war creating any real recession. Repatriation of jobs from abroad will accelerate.

Amazon Splits 20:1, mimicking NVIDIA’s and Tesla’s earlier moves. Although it should make no difference, such splits are always a positive, as more retail investors can buy Alphabet at $145 than $2,900. Option traders too. The split takes place in July

Rents Rise at fastest rate in 30 years. The index for rentals of primary residences as collected by the Bureau of Labor Statistics is now the highest since 1987. Rents accounted for 40% of the big jump in the CPI in February. Inflation will get worse before it gets better.

Russian Credit Default Swaps Hit 34% Yields, indicating an extremely high probability of default. Some $100 million in interest payments are due next week, but with virtually all bank accounts frozen and kicked out of SWIFT, they have no means to pay.

The largest holders of Russian debt, like Pimco, Voya, and Capital Group, are taking big hits this morning. Who knows, they might be a BUY here. After all, those defaulted Chinese railroad bonds paid off, pennies on the dollar and 100 years after issue. Are confederate state bonds next?

My Ten-Year View

When we come out the other side of pandemic, we will be perfectly poised to launch into my new American Golden Age, or the next Roaring Twenties. With interest rates still at zero, oil cheap, there will be no reason not to. The Dow Average will rise by 800% to 240,000 or more in the coming decade. The American coming out the other side of the pandemic will be far more efficient and profitable than the old. Dow 240,000 here we come!

With near-record volatility, my February month-to-date performance catapulted to a blistering 15.56%. My 2022 year-to-date performance ended at a chest-beating 30.15%. The Dow Average is down -7.6% so far in 2022. It is the great outperformance on an index since Mad Hedge Fund Trader started 14 years ago.

My only new trade this week was to use a $4.00 dive in the (TLT) to go from a single to a double long in the bond market. That leaves me 60% invested and 50% in cash, waiting for the next capitulation selloff. So, I am 3X short the (TLT), 2X long the (TLT), and 1X long Tesla.

That brings my 13-year total return to 538.24%, some 2.10 times the S&P 500 (SPX) over the same period. My average annualized return has ratcheted up to 44.54%, easily the highest in the industry. Five of six of these positions expire on March 18, in four days.

We need to keep an eye on the number of US Coronavirus cases that's close to 80 million and deaths of around 970,000, which you can find here. Growth of the pandemic has virtually stopped, with new cases down 96% in a month.

On Monday, March 14 at 7:00 AM EST, US Consumer Inflation Expectations for February are printed.

On Tuesday, March 15 at 7:30 AM, the Producer Price Index for February is released.

On Wednesday, March 16 at 10:00 AM, the Federal Reserve will announce the first interest rate rise in five years, almost certainly a quarter point.

On Thursday, March 17 at 7:30 AM, Weekly Jobless Claims are published. Housing Starts and Building Permits for February are published.

On Friday, March 18 at 7:00 AM, the Existing Home Sales for February are announced. At 2:00 PM, the Baker Hughes Oil Rig Count is out.

As for me, someone commented that I walk kind of funny the other day, and the memories flooded back.

In 1975, The Economist magazine in London heard rumors that a large part of the population was getting slaughtered in Cambodia. We expected this to happen after the fall of Vietnam, but not in the Land of the Khmers. So my editor, Peter Martin, sent me to check it out.

Hooking up with a right-wing guerrilla group financed by the CIA was the easy part. Humping 100 miles in 100-degree heat wasn’t.

We eventually came to a large village that was completely deserted. Then my guide said, “Over here.” He took me to a nearby cave containing the bodies of over 1,000 women, children, and old men that had been there for months.

I’ll never forget that smell.

With the evidence and plenty of pictures in hand, we started the trek back. Suddenly, there was a large explosion and the man 20 yards in front of me disappeared. He had stepped on a land mine. Then the machine gun fire opened up. It was an ambush.

I picked up an M-16 to return fire, but it was bent, bloody, and unusable. I picked up a second rifle and fired until it was empty. Then everything suddenly went black.

I woke up days chained to a palm tree, covered in shrapnel wounds, a prisoner of the Khmer Rouge. Maggots infested my wounds, but I remembered from my Tropical Diseases class at UCLA that I should leave them alone because they only eat dead flesh and would prevent gangrene. That class saved my life. Good thing I got an “A”.

I was given a bowl of rice a day to eat, which I had to gum because it was full of small pebbles and might break my teeth. Farmers loaded their crops with these so the greater weight could increase their income. I spent my time pulling shrapnel out of my legs with a crude pair of plyers.

Two weeks later, the American who set up the trip for me showed up with cases of claymore mines, rifles, ammunition, and antibiotics. My chains were cut and I began the long walk back to Thailand.

It’s nice to learn your true value.

Back in Bangkok, I saw a doctor who attended to the 50 caliber bullet that grazed my right hip. It was too old to sew up so he decided to clean it instead. “This won’t hurt a bit,” he said as he poured in hydrogen peroxide and scrubbed it with a stiff plastic brush.

It was the greatest pain of my life. Tears rolled down my face.

But you know what? The Economist got their story and the world found out about the Great Cambodian Genocide, where 3 million died. There is a museum in Phnom Penh devoted to it today.

So, if you want to know why I walk funny, be prepared for a long story. I still set off metal detectors.

Stay Healthy,
John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader

 

 

 

 

 

 

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2021/11/john-thomas-cambodia-1975.png 622 450 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-14 09:02:422022-03-14 12:57:52The Market Outlook for the Week Ahead, or Recession Fears Arise
Mad Hedge Fund Trader

March 11, 2022

Tech Letter

Mad Hedge Technology Letter
March 11, 2022
Fiat Lux

Featured Trade:

(AMAZON MEANS BUSINESS)
(AMZN), (AAPL), (TSLA), (GOOGL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-11 16:04:392022-03-11 16:17:57March 11, 2022
Mad Hedge Fund Trader

Amazon Means Business

Tech Letter

The blockbuster announcement from Amazon (AMZN) regarding their 20:1 stock split is a big deal, and don’t listen to the charlatans who say otherwise.

Sure, on paper, the business model will be thriving just like it has been since its inception, but this piece of financial manipulation is genius.

Just think about it.

The reason for Amazon to need a stock split in the first place is because the stock has gone from the bottom left to the top right over time.

The best and most successful companies frequently execute stock splits and so even if one wants to spin it as a problem, it’s a problem that I wouldn’t mind having myself.

Splits are often a bullish sign since valuations get so high that the stock may be out of reach for smaller investors trying to stay diversified. Investors who own a stock that splits may not make a lot of money immediately, but they shouldn't sell the stock since the split is likely a positive sign.

Nominally cheap stocks have a massive psychological effect on the average investor.

I also don’t buy the BS about fractional shares, it’s like owning half a car.

Nobody wants that.

Investors also clamor for round numbers.

Would you rather own 5 shares of AMZN or 100 after the stock split?

Human psychology can’t be discounted here and, true to form, stock splits have been the precursor to even higher share prices.

Many companies decide to rinse and repeat and AMZN also unearthed a tidy $10 billion stock buyback plan.

So it’s no shock that this will be Amazon's 4th stock split in its history. The last split came in September 1999.

If shareholders approve of the split, it will begin trading on the new basis on June 6.

Big tech behemoths made hay when the sun was shining during the pandemic, and now they want to make it easy for the simple investors to get back into shares.

Bravo to them.

Other companies of its ilk have also partaken in stock splits like Tesla and Alphabet.

So this isn’t out of left field.

It just so happens that at the time of the stock split announcement, big tech has been the most oversold in the past 5 years.

Apple (AAPL) split its stock 4-for-1 in 2020s. Tesla's (TSLA) 5-for-1 stock split also occurred in 2020. Alphabet's (GOOGL) 20-for-1 stock split was announced in February.

Granted, at a fundamental level, things won’t be different at Amazon.

This doesn’t change the innards of the machine that was built for financial engineering from share buybacks to stock splits and the timing of it is also an important lever as every company tries to max out its genetic makeup.

Amazon shares are down about 9% in the past year, but I would attribute that more to too fast too soon.

Then we were hit by the onslaught of higher interest rate expectations and then the Ukrainian war.

Let’s be honest, the first 3 months of this year have been an absolute blood bath for equities, and AMZN doesn’t trade in a vacuum.

The extra kick in the teeth was the supply chain problem for the ecommerce juggernaut.

AMZN will come back as market sentiment starts to heal itself.

War won’t be a ubiquitous event around the Western world and I view the military escalation as an anomaly.

It’s not like AMZN is operating in Russia as well, or China for that matter.

It’s true that the events of the last few weeks have shined a spotlight on non-Democratic countries as a poor environment for business and in absolute disregard of the rule of law.

AMZN needs to operate in places where the law has teeth, otherwise, delivery packages would get stolen half the time with no recourse.

I feel the timing of the stock split is also indicative of a near short-term bottom in tech stocks.

 

amazon stock split

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-11 16:02:352022-03-25 19:25:29Amazon Means Business
Mad Hedge Fund Trader

March 11, 2022 - Quote of the Day

Tech Letter

“Don't chase a girl, let the girl chase you.” – Said Founder of Softbank Masayoshi Son

https://www.madhedgefundtrader.com/wp-content/uploads/2020/02/masayoshi.png 243 270 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-11 16:00:312022-03-11 16:32:26March 11, 2022 - Quote of the Day
Mad Hedge Fund Trader

March 11, 2022

Diary, Newsletter, Summary

Global Market Comments
March 11, 2022
Fiat Lux

Featured Trade:

(THE MAD HEDGE TRADERS & INVESTORS SUMMIT IS ON FOR MARCH 14-16)
(A REFRESHER COURSE AT SHORT SELLING SCHOOL),
(SH), (SDS), (PSQ), (DOG), (RWM), (SPXU), (AAPL), (TSLA),
 (VIX), (VXX), (IPO), (MTUM), (SPHB), (HDGE)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-11 09:06:302022-03-11 16:07:50March 11, 2022
Mad Hedge Fund Trader

March 10, 2022

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
March 10, 2022
Fiat Lux

Featured Trade:

(COULD THIS BE THE NEXT BIOTECH BUYOUT CANDIDATE?)
(BLUE), (AZN), (ABBV), (BMY), (VRTX), (CRSP)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-10 17:02:052022-03-10 19:25:57March 10, 2022
Mad Hedge Fund Trader

Could This Be the Next Biotech Buyout Candidate?

Biotech Letter

What is the common denominator of giant drugmakers AstraZeneca (AZN), AbbVie (ABBV), and Bristol Myers Squibb (BMY)?

Aside from being three of the biggest healthcare companies across the globe, all three have also completed high-profile acquisitions amid the pandemic.

AstraZeneca acquired Alexion Pharmaceuticals for $39 billion in December 2020.

Meanwhile, AbbVie wrapped up its whopping $63 billion acquisition of Allergan in May 2020.

As for BMY, this biopharma titan followed its jaw-dropping $74 billion acquisition of Celgene with a $13 billion merger with MyoKordia.

Since then, these deals have bolstered the lineups and deepened the pipelines of all three drugmakers, helping them secure their dominance in the healthcare space.

As for the acquirees, they also benefited from the transactions, particularly those struggling to get through tough situations prior to getting bought out.

With that in mind, it looks like the biotechnology and healthcare sector has another potential high-profile acquisition candidate: Bluebird Bio (BLUE).

Bluebird Bio has recently fallen from investors’ grace following multiple setbacks.

The biotechnology company, once considered a trail-blazer in the gene therapy space, now finds itself without a CFO and left behind by competitors.

Its peers, who were initially eons away in terms of pipeline development, have figured out ways to work around Bluebird’s patents and even managed to outpace the company in launching new gene therapies to market.

Given all these factors, it is no surprise that investing in Bluebird bio has become synonymous with a recycler searching for value in random scraps and parts.

Over the last three years, Bluebird Bio’s shares have plummeted by more than 90%. From a $1.39 billion market capitalization, it is now at roughly $330 million.

That is a horrible performance based on any metric.

Bluebird bio has faced several headwinds that caused its stocks to fall apart.

One problem is the delay in the company’s Biologics License Application in the US for its transfusion-dependent beta-thalassemia treatment, LentiGlobin.

Bluebird Bio initially planned to complete this rare blood disorder therapy’s application by the second half of 2020. However, the company failed to submit some information requested by the FDA.

Another LentiGlobin-related issue is the temporary pause on the clinical trial for sickle cell disease treatment. Eventually, the suspension was lifted, but not before investors scurried away from the stock, following back-to-back concerns over the same treatment.

Other aggravating factors include Bluebird’s move to exit the European market following disagreements over the pricing of some of its gene therapies.

These issues saw Bluebird’s market cap sink, positioning it lower than rival gene-editing companies today.

Needless to say, this deeply discounted value could attract a bigger and expanding biopharma seeking to dip its toes in the gene-editing space.

While Bluebird might be struggling these days, it remains a promising company thanks to its candidates.

This becomes even more exciting since the company announced its plans to concentrate on severe genetic diseases. Although this is a small niche, there’s massive potential in this market.

A strong candidate in its roster is Zynteglo, which gained regulatory approval in 2019 and has yet to reach blockbuster status.

Patients with beta-thalassaemia normally have no other choice but to get blood transfusions regularly. Zynteglo drastically challenges this standard by offering a one-time curative treatment. In fact, saying that this is a life-changing breakthrough is an understatement.

Another potential blockbuster is Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy. This neurological disease is extremely rare, affecting only 50 patients in the US annually.

As for its pipeline, Bluebird has three major candidates nearing FDA approval in the US. This means 2022 and 2023 will be critical years for the company.

The first product is Lenti-D, which is similar to Skysona. If things go according to plan, then this treatment might receive the green light by August 2022.

Another product is Beti-cel, which was initially launched as Zynteglo. When this successfully penetrates the US market, this first-ever gene therapy option for beta-thalassemia will rake in roughly $1.87 billion by 2024.

Considering the potential of this market, Beti-cel inevitably finds itself facing off strong competitors in the space.

Thus far, the strongest is Vertex Pharmaceuticals (VRTX), which recently announced an additional $900 million investment in its collaboration with CRISPR Therapeutics (CRSP).

The third candidate is Lovo-cel, which is a sickle cell disease treatment.

This could be a major product for Bluebird, given the over 100,000 patients in the US alone that the company can target.

The goal is to finish the validation process by 2022 and submit Lovo-cel for approval by the first quarter of 2023.

Outside its pipeline candidates and approved products, Bluebird's manageable debt is another thing that makes it attractive for a potential buyout.

After all, cash is king, especially when it comes to biotechnology companies.

At the moment, Bluebird still holds roughly $442 million in the bank, and $46 million of this is restricted.

This indicates unrestricted liquid assets of approximately $396 million—an amount higher than its current market cap.

Consequently, this will allow Bluebird to comfortably weather at least the rest of the year until 2023.

It possesses a relatively solid secure position to hold itself together until its pending candidates start raking in revenues on their own.

Admittedly, Bluebird Bio has had several challenging years. There will still be uncertainties ahead, but it’s undeniable just how promising the company is at this point.

Overall, this stock is worth serious consideration, particularly for companies looking to get a head start in the gene-editing sector.

bluebird

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-10 17:00:092022-03-25 14:15:05Could This Be the Next Biotech Buyout Candidate?
Mad Hedge Fund Trader

March 10, 2022

Bitcoin Letter

Mad Hedge Bitcoin Letter
March 10, 2022
Fiat Lux

Featured Trade:

(WASHINGTON GETS SERIOUS ABOUT CRYPTO)
(BTC), (FB)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-10 15:04:342022-03-10 16:22:55March 10, 2022
Mad Hedge Fund Trader

Washington Gets Serious About Crypto

Bitcoin Letter

U.S. President Joe Biden signing a crypto executive order is more bark than bite.

It doesn’t mean that anything really will happen, especially in the short term.

Optics are quite important for the current American administration, and I believe this is another instance.

Throw the crypto fanatics a bone and hype it up like a transformational moment when it’s not.

If you live in a world of hard outcomes, then this isn’t one of them.

Granted, it’s a step in the right direction, but no meaningful legislation has been enacted yet and I highly doubt that anything concrete gets done before the next administration.

I won’t get into the business of hyping up this announcement of “establishing a framework” for the digital gold because it echoes the direction they were supposed to go with big tech.

Big tech was supposed to get regulated to the utmost, but nothing ever came of it.

The only tech firm that blew up was Meta or Facebook (FB), but that was more about self-inflicted wounds than anything else.

Big tech is largely unscathed from the historical behavior, and nothing has changed in terms of the handling of personal data and its integrity.

Turning a blind eye than rather dealing with issues has been sort of the consensus for anything really controversial with big business.

I don’t believe the administration will lift a finger and plan to treat crypto as politicking even to please optics.

This will create a situation where they can straddle positions on both sides so they can claim innocence if something goes wrong with crypto or take the credit if crypto develops.

The reports will dish up buzz words like “historic” and “unprecedented.”

The order was finally signed Wednesday. It calls on federal agencies to take a unified approach to regulation and oversight of digital assets, according to a White House fact sheet.

A unified approach could also mean that nobody does anything together so we will need to see more substance out of Washington.

The Biden administration is calling on the Treasury to assess and develop policy recommendations on crypto.

Even if recommendations can be decided upon, it doesn’t mean that it will be net positive for Bitcoin’s price.

Last month, U.S. officials seized $3.6 billion worth of bitcoin — their biggest seizure of cryptocurrencies ever — related to the 2016 hack of crypto exchange Bitfinex.

Following Russia’s invasion of Ukraine, authorities are now also concerned about the possible use of crypto in helping sanctioned Russian individuals and companies evade the restrictions.

There is illegal activity that the government wants to stamp out and writing the rules makes it easier to do that.

The Biden administration also wants to explore a digital version of the dollar which is copying the Chinese playbook.

Much of the policy is strategizing relative to what China and Russia are doing and he fell short of saying that the US will create a digital dollar.

Again, it’s more of the optics of saying the government need “urgency” on research and development of a potential digital dollar which doesn’t really mean anything.

The Federal Reserve last year began work on exploring the potential issuance of a digital dollar. The central bank released a long-awaited report detailing the pros and cons of such virtual money but didn’t take a position yet on whether it thinks the U.S. should issue one.

These announcements are a far cry from real policy moves.

It’s great that more resources will be thrown at the asset class but research and urgency don’t mean much in terms of hard victories.

Short-term, this Eastern European crisis has been a massive shot across the bow for Bitcoin fanatics because it has proven that during a possible nuclear war, nobody will buy Bitcoin.

After the dead cat bounce, there was another draconian sell-off this morning in Bitcoin with the asset down 7%, again, diving below $40,000.

The bad price action was created by the 7.9% CPI print and Bitcoin was supposed to be an inflation hedge, but the price action suggests it performs poorly as an inflation hedge.

The jury is out but Bitcoin has failed some major tests this year and it will be a hard slog for the rest of the year.

Sell the rallies until the backdrop and variables change for the better.

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-10 15:02:302022-03-10 17:05:01Washington Gets Serious About Crypto
Mad Hedge Fund Trader

Quote of the Day - March 10, 2022

Bitcoin Letter

“Setting regulatory certainty is very important for bitcoin. I'm opposed to the regulations, but the bitcoin businesses need to know the rules of the game in order to move ahead.” – Said Crypto Entrepreneur Roger Ver

https://www.madhedgefundtrader.com/wp-content/uploads/2022/03/roger-ver-e1646947278659.png 300 254 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-03-10 15:00:272022-03-10 16:22:20Quote of the Day - March 10, 2022
Page 10 of 15«‹89101112›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top